BHVNbenzinga

Reported Earlier, Biohaven's Troriluzole NDA For Rare Disease SCA Receives Three-Month PDUFA Extension For Full FDA Review

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 15, 2025 by benzinga

    Reported Earlier, Biohaven's Troriluzole NDA For Rare Disease SCA Receives Three-Month PDUFA Extension For Full FDA Review | BHVN Stock News | Candlesense